Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn.
How we work:
- PIONEER: We are courageous, resilient and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.
- COLLABORATE: We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine.
- BELONG: We recognize our differences, inviting curiosity and inclusivity, so that our people are valued, seen, and heard.
How you’ll make an impact:
- Lead and grow Kymera's PBPK/PBBM capability, defining workflows, standards, best practices, and software strategy.
- Apply translational PBPK/PBBM to predict human PK and oral bioavailability across species, formulations, and dose levels, and to support first-in-human dose selection.
- Partner with CMC to support formulation selection and optimization through PBBM.
- Develop IVIVC and mechanistic in vitro-in vivo dissolution models (e.g., DDDPlus) to link drug product performance to in vivo behavior, establish clinically relevant specifications, and support formulation bridging.
- Apply PBPK to clinical pharmacology questions such as drug-drug interactions, food effects, special populations (pediatrics and organ impairment) to inform clinical study design and dose adjustments.
- Embed within multidisciplinary project teams to provide real-time study-design support and rapid model iteration as new data emerge.
- Liaise with collaboration partners and CROs to generate data and analyses.
- Represent DMPK perspective on project teams as portfolio needs require.
- Prepare reports and summary documents to support regulatory submissions and respond independently to health authority questions.
- PhD or PharmD (or equivalent) in pharmaceutical sciences, DMPK, pharmacokinetics, chemical/biomedical engineering, or a related field, with 7+ years of hands-on PBPK/PBBM experience.
- Deep understanding of ADME/DMPK and biopharmaceutics principles.
- Significant hands-on GastroPlus experience (required), with a demonstrated ability to manage and deliver modeling work independently.
- Proven ability to build mechanistic absorption and whole-body PBPK models, translate preclinical data into human PK predictions for oral small molecules, and deliver practical, timely, and impactful recommendations to advance programs.
- Experience modeling oral molecules with challenging developability profiles, including poorly soluble and/or permeable compounds and beyond-rule-of-five modalities such as targeted protein degraders (preferred).
- Proficiency in scripting for data handling, workflow automation, and model QC (e.g., R, Python, or MATLAB).
- Simcyp modeling experience (preferred).
- Track record of PBPK/PBBM contributions to regulatory submissions such as IND, NDA, DDI, or biopharmaceutics packages (preferred).
- DMPK project representative experience (strongly preferred).
- Demonstrated ability to work collaboratively with cross-functional teams in a fast-paced environment with changing priorities (required).
- Ability to communicate clearly and concisely with specialist and non-specialist stakeholders, including leadership and project management (required).
Kymera Therapeutics is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment. All applicants will receive consideration for employment without regard to race, color, religion, creed, gender, national origin, age, disability, veteran status, pregnancy, sex, marital status, gender expression or identity, genetic information, sexual orientation, citizenship, or any other legally protected class.
Compensation
- Kymera offers a competitive compensation package that recognizes both results and capabilities through market-based, performance-driven pay.
- The anticipated base salary range for this role is $160,000 – $275,000, with eligibility for annual bonus, equity participation, and comprehensive benefits.
- Actual salary is based on a holistic evaluation of the specific role/level as well as each candidate’s depth of experience and the capabilities they bring to the position.
Skills Required
- PhD or PharmD (or equivalent) in pharmaceutical sciences, DMPK, pharmacokinetics, chemical/biomedical engineering, or related field with 7+ years of hands-on PBPK/PBBM experience.
- Deep understanding of ADME/DMPK and biopharmaceutics principles.
- Significant hands-on GastroPlus experience with ability to manage and deliver modeling work independently.
- Proven ability to build mechanistic absorption and whole-body PBPK models and translate preclinical data into human PK predictions for oral small molecules.
- Proficiency in scripting for data handling, workflow automation, and model QC (e.g., R, Python, or MATLAB).
- Demonstrated ability to work collaboratively with cross-functional teams in a fast-paced environment with changing priorities.
- Ability to communicate clearly and concisely with specialist and non-specialist stakeholders, including leadership and project management.
- Experience developing IVIVC and mechanistic in vitro-in vivo dissolution models (e.g., DDDPlus) to link drug product performance to in vivo behavior and support formulation bridging.
- Experience modeling oral molecules with challenging developability profiles, including poorly soluble and/or permeable compounds and beyond-rule-of-five modalities such as targeted protein degraders.
- Simcyp modeling experience.
- Track record of PBPK/PBBM contributions to regulatory submissions such as IND, NDA, DDI, or biopharmaceutics packages.
- DMPK project representative experience.
Kymera Therapeutics Compensation & Benefits Highlights
The following summarizes recurring compensation and benefits themes identified from responses generated by popular LLMs to common candidate questions about Kymera Therapeutics and has not been reviewed or approved by Kymera Therapeutics.
-
Fair & Transparent Compensation — Pay is considered market‑competitive for core scientific and leadership roles, with clearly posted ranges visible for U.S. openings. Feedback suggests strong base pay aligns with comments about high salary and good pay.
-
Equity Value & Accessibility — Employees are eligible to participate in broad‑based equity programs, including an equity incentive plan and an ESPP. Feedback suggests this ownership opportunity can meaningfully augment total compensation in a growth‑focused setting.
-
Leave & Time Off Breadth — Company‑wide office shutdowns, standard PTO, and summer schedules are promoted to help people unplug. Feedback suggests these practices contribute to a well‑rounded time‑off offering.
Kymera Therapeutics Insights
What We Do
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years








